Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study

American Journal of Psychiatry

Volumn 165, Issue 8, 2008, Pages 988-995

  Gründer, Gerhard ^a   Fellows, Christine ^b   Janouschek, Hildegard ^b   Veselinovic, Tanja ^b   Boy, Christian ^b   Bröcheler, Anno ^b   Kirschbaum, Katrin M ^b   Hellmann, Sandra ^b   Spreckelmeyer, Katja M ^b   Hiemke, Christoph ^b   Rösch, Frank ^b   Schaefer, Wolfgang M ^b   Vernaleken, Ingo ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FALLYPRIDE; FLUORINE 18; LORAZEPAM; ZOPICLONE;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN REGION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; HUMAN; INSOMNIA; MALE; NONLINEAR REGRESSION ANALYSIS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BINDING SITES; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 48949098297     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.07101574     Document Type: Article

References (37)

1. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
2. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293
3. 11C]raclopride. Neuropsychopharmacology 2002; 27248-27259
4. 1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007; 164:1411-1417
5. Gründer G, Carlsson A, Wong DF: Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60:974-977
6. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995; 152:1444-1449
7. 2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553-559
8. 3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31:1027-1035
9. 2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31:1991-2001
10. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW: Limbic selectivity of clozapine. Lancet 1997; 350:490-491
11. 123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology 2000; 150:132-140
12. 123I]-epidepride SPET study. J Clin Psychopharmacol 2003; 23:5-14
13. 2 receptors in antipsychotic response: a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007; 32:1209-1215
14. 11C]FLB 457. Am J Psychiatry 2001; 158:926-930
15. 2-like dopamine receptors by amisulpride in brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7:421-430
16. 2 receptor ligands of different affinities. J Nucl Med 2005; 46:964-972
17. 3 receptors. Synapse 2002; 46:170-188
18. 2-like dopamine receptors. Bioorg Med Chem 2007; 15:6819-6829
19. 18F]desmethoxyfallypride. J Nucl Med 2003; 44109-44116
20. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4(3 Pt 1):153-158
21. 2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 2001; 25:476-488
22. 3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005; 30:2283-2289
23. 2 receptor density and affinity in the human brain using PET. Neuroimage 2004; 22:794-803
24. Kirschbaum KM, Muller MJ, Zernig G, Saria A, Mobascher A, Malevani J, Hiemke C: Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem 2005; 51:1718-1721
25. Kirschbaum KM, Muller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C: Serum levels of aripiprazole and dehydroaripiprazole, clinical response, and side effects. World J Biol Psychiatry (E-pub ahead of print, May 11, 2007)
26. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB: Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20:612-627
27. Oosterhuis M, Van De Kraats G, Tenback D: Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient (letter). Am J Psychiatry 2007; 164:175
28. Hendset M, Hermann M, Lunde H, Refsum H, Molden E: Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63:1147-1151
29. Mallikaarjun S, Salazar DE, Bramer SL: Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44:179-187
30. 2 atypical antipsychotics (letter). Am J Psychiatry 2005; 162:1984-1985
31. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001; 158:360-369
32. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179:503-508
33. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106:433-438
34. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38
35. Brown RM, Crane AM, Goldman PS: Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res 1979; 168:133-150
36. Pehek EA: Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. J Pharmacol Exp Ther 1999; 289:14-23
37. Garris PA, Wightman RM: Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 1994; 14:442-450